Fig. 4From: High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisionsThe prognostic value of ETS2 expression in the second cohort. a OS and b EFS of 329 AML patients and the subgroup of 173 patients with NCCN intermediate-risk. c OS and d EFS of the 156 CN-AML patients and 121 AML patients in the ELN Intermediate-I categoryBack to article page